Effects of Losartan and Antiretroviral Regimen Containing Raltegravir in Fibrosis Inflammation
Phase of Trial: Phase IV
Latest Information Update: 22 Jul 2017
At a glance
- Drugs Losartan (Primary) ; Raltegravir (Primary) ; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate; Emtricitabine/tenofovir disoproxil fumarate
- Indications HIV infections
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 18 Feb 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 25 Feb 2014 Planned End Date changed from 1 Jun 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov record.